What is Onivyde and What is it Used For?
Onivyde (irinotecan liposome injection) is a chemotherapy drug used to treat pancreatic cancer. It is specifically indicated for patients with metastatic pancreatic adenocarcinoma whose disease has progressed after initial gemcitabine-based chemotherapy [1].
How Does Onivyde Work?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. In this formulation, the irinotecan is encapsulated within tiny lipid spheres called liposomes. This delivery method is designed to alter the drug's pharmacokinetics, potentially leading to a longer circulation time and sustained release of irinotecan in the body. Once released, irinotecan interferes with DNA replication and repair in cancer cells, ultimately leading to their death [1].
What are the Common Side Effects of Onivyde?
The most frequently reported side effects of Onivyde include diarrhea, vomiting, nausea, fatigue, neutropenia (low levels of neutrophils, a type of white blood cell), and leukopenia (low levels of white blood cells) [1]. Diarrhea, in particular, can be severe and may require immediate medical attention. Patients are often advised to take anti-diarrheal medication as prescribed by their doctor and to stay hydrated [1].
What is the Typical Treatment Regimen for Onivyde?
Onivyde is typically administered intravenously over 90 minutes every two weeks [1]. The recommended starting dose is 80 mg/m² [1]. The treatment schedule and dosage may be adjusted by a healthcare professional based on individual patient response and tolerance.
Are There Any Serious Risks Associated with Onivyde?
Serious risks associated with Onivyde treatment include severe diarrhea, myelosuppression (suppression of bone marrow activity, leading to low blood cell counts), and hypersensitivity reactions [1]. Patients should be closely monitored by their healthcare team for these potential complications.
When Does the Patent for Onivyde Expire?
Information on the patent expiry for Onivyde can be found on specialized patent tracking websites such as DrugPatentWatch.com [2]. These resources provide details on patent dates, expiry, and potential challenges.
Who Manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [1].
What Are the Alternatives to Onivyde for Pancreatic Cancer?
For patients with metastatic pancreatic adenocarcinoma who have progressed on gemcitabine-based chemotherapy, Onivyde is an option. Other treatment strategies may involve different chemotherapy regimens, targeted therapies, or immunotherapies, depending on the patient's specific situation and tumor characteristics. Clinical trials also offer access to investigational treatments [3].
How Does Onivyde Compare to Other Pancreatic Cancer Treatments?
Onivyde is a specific chemotherapy agent for a particular stage and patient population within pancreatic cancer treatment. Its efficacy and side effect profile are considered in the context of other available therapies. For instance, in clinical trials, Onivyde in combination with other agents demonstrated improved overall survival compared to those treated with placebo and best supportive care in patients with metastatic pancreatic adenocarcinoma whose disease progressed after gemcitabine-based therapy [4].
What Clinical Data Supports the Use of Onivyde?
The efficacy and safety of Onivyde were evaluated in clinical trials. A key study involved patients with metastatic pancreatic adenocarcinoma who had previously received gemcitabine-based chemotherapy. Results showed a statistically significant improvement in overall survival for patients treated with Onivyde plus a combination of fluorouracil and leucovorin compared to those who received best supportive care and placebo plus fluorouracil and leucovorin [4].
---
Sources:
[1] https://www.drugpatentwatch.com/drugs/onivyde
[2] https://www.drugpatentwatch.com/
[3] https://www.cancer.gov/types/pancreatic/treatment
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1515042